Hangzhou Yaodaixu Digital Technology Co., Ltd. is advancing its angel round financing, planning to raise RMB 12 million by transferring 20% of its equity, corresponding to a post-money valuation of RMB 60 million. The company develops AI-driven intelligent management software for drug and medical device GMP compliance, aiming to shift GMP quality management from "in-process recording, isolated modules, and loose logic" to "pre-warning, in-process assistance, and fully linked workflows". The GMP system comprises more than 20 core modules, including documents, training, change, deviation, CAPA, suppliers, LIMS, and audit, but most mainstream software features independently deployed modules and isolated data, creating "data silos". Industry AI application remains at the L1 level of assisted Q&A, with vendors integrating general large model APIs without vertical fine-tuning or real-time regulatory updates. Policy signals support this shift, including the "Implementation Opinions on 'Artificial Intelligence + Drug Regulation'" issued by NMPA (No. 6 [2026] of the General Office of National Medical Products Administration), the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" (No. 79 [2025] of the Ministry of Industry and Information Technology), and the new "Good Manufacturing Practices for Medical Devices" (No. 107 of 2025). Yaodaixu's products integrate more than 20 GMP modules on